Do antipsychotic drugs increase seizure frequency in epilepsy patients?

European Neuropsychopharmacology

Volumn 24, Issue 11, 2014, Pages 1738-1744

  Okazaki, Mitsutoshi ^a   Adachi, Naoto ^a,b   Akanuma, Nozomi ^c   Hara, Koichiro ^d   Ito, Masumi ^a,e   Kato, Masaaki ^a,f   Onuma, Teiichi ^a,f  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b Kidney Center Sapporo South One Hospital   (Japan)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d Asai Hospital   (Japan)

^e Jozen Clinic   (Japan)

^f Musashino Kokubunji Clinic   (Japan)

Author keywords

Antipsychotic drugs; Epilepsy; Psychosis; Seizure; Treatment

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; RISPERIDONE; SULPIRIDE; ANTICONVULSIVE AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; DEMOGRAPHY; EPILEPSY; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GENERALIZED EPILEPSY; HALLUCINATION; HUMAN; INTRACTABLE EPILEPSY; KRUSKAL WALLIS TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; OUTCOME ASSESSMENT; PSYCHOSIS; RANK SUM TEST; SEIZURE; TREATMENT OUTCOME; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; DRUG COMBINATION; JAPAN; MENTAL DISORDERS; RETROSPECTIVE STUDY; YOUNG ADULT;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; JAPAN; MENTAL DISORDERS; RETROSPECTIVE STUDIES; SEIZURES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84918537368     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.09.012     Document Type: Article

References (37)

1. Adachi N. Treatment of mental disorders in epilepsy patients. Jpn. J. Psychiatry Treat. 2005, 20(Suppl):S370-S373. ([in Japanese]).
2. Adachi N., Akanuma N., Ito M., Okazaki M., Kato M., Onuma T. Interictal psychotic episodes in epilepsy: duration and associated clinical factors. Epilepsia 2012, 53:1088-1094.
3. Adachi N., Alarcon G., Binnie C.D., Elwes R.D.C., Polkey C.E., Reynolds E.H. Predictive value of interictal epileptiform discharges during non-REM sleep on scalp EEG recordings for the lateralization of epileptogenesis. Epilepsia 1998, 39:628-632.
4. Adachi N., Kanemoto K., de Toffel B., Akanuma N., Oshima T., Mohan A., Sachdev P. Basic treatment principles for psychotic disorders in patients with epilepsy. Epilepsia 2013, 54(Suppl 1):S19-S33.
5. Alldredge B.K. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 1999, 53(Suppl 2):S68-S75.
6. Alper K., Schwartz K.A., Kolts R.L., Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol. Psychiatry 2007, 62:345-354.
7. Behere R.V., Anjith D., Rao N.P., Venkatasubramanian G., Gangadhar B.N. Olanzapine-induced clinical seizure: a case report. Clin. Neuropharmacol. 2009, 32:297-298.
8. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989, 30:389-399. Commission on Classification and Terminology of the International League Against Epilepsy.
9. Fitzgerald P.B., Brown T.L., Daskalakis Z.J., Kulkarni J. A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia. Psychopharmacology 2002, 162:74-81.
10. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2012, 167:686-693.
11. Gross A., Devinsky O., Westbrook L.E., Wharton A.H., Alper K. Psychotropic medication use in patients with epilepsy: effect on seizure frequency. J. Neuropsychiatry Clin. Neurosci. 2000, 12:458-464.
12. Gudmundsson G. Epilepsy in Iceland. Acta Neurol. Scand. 1966, 43(Suppl 25):S1-S124.
13. Haddad P.M., Sharma S.G. Adverse effects of atypical antipsychotics. Differential risk and clinical implications. CNS Drugs 2007, 21:911-936.
14. Hara K., Adachi N., Akanuma N., Ito M., Okazaki M., Kato M., Onuma T. Effects of antipsychotic drugs on the duration of interictal psychotic episodes in epilepsy patients. Epilepsy Behav. 2013, 27:342-345.
15. Hedges D., Jeppson K., Whitehead P. Antipsychotic medication and seizures: a review. Drug Today 2003, 39:551-557.
16. Itil T.M., Soldatos C. Epileptogenic side effects of psychotropic drugs. J. Am. Med. Assoc. 1980, 244:1960-1963.
17. Karouni M., Arulthas S., Larsson P.G., Rytter E., Johannessen S.I., Landmark C.J. Psychiatric comorbidity in patients with epilepsy: a population-based study. Eur. J. Clin. Pharmacol. 2010, 66:1151-1160.
18. Kerr M., Mensah S., Besag F., de Toffol B., Ettinger A., Kanemoto K., Kanner A., Kemp S., Krishnamoorthy E., LaFrance W.C., Mula M., Schmitz B., Tabertz van Elst L., Troller J., Wilson S.J. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011, 52:2133-2138.
19. Koch-Stoecker S. Antipsychotic drugs and epilepsy: indications and treatment guidelines. Epilepsia 2002, 43(Suppl 2):S19-S24.
20. Kumlien E., Lundberg P.O. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure 2010, 19:69-73.
21. Lamgguth B., Eichhammer P., Spranz C., Landgrebe M., Sand P., Hajak G. Moduration of human motor cortex excitability by quetiapine. Psychopharmacology 2008, 196:623-629.
22. Lertxundi U., Hernandez R., Medrano J., Domingo-Echaburu S., García M., Aguirre C. Antipsychotics and seizures: higher risk with atypicals?. Seizure 2013, 22:141-143.
23. Logothetis J. Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 1967, 17:869-877.
24. Markowitz J.C., Brown R.P. Seizures with neuroleptics and antidepressants. Gen. Hosp. Psychiatry 1987, 9:135-141.
25. Melduram B.S. The effect of psychotropic drugs on the seizure threshold: animal studies. The Psychopharmacology 1988, 107-117. John Wiley & Sons, Chichester. M.R. Trimble (Ed.).
26. Monte-Silva K., Ruge D., Teo J.T., Paulus W., Rothwell J.C., Nitsche M.A. D2 receptor block abolishes theta burst stimulation-induced neuroplasticity in the human motor cortex. Neuropsychopharmacology 2011, 36:2097-2102.
27. Nitsche M.A., Kuo M.F., Grosch J., Berger C., Monte-Silva K., Paulus W. D1-receptor impact on neuroplasticity in humans. J. Neurosci. 2008, 29:2648-2653.
28. Ojemann L.M., Baugh-Bookman C., Dudley D.L. Effect of psychotropic medications on seizure control in patients with epilepsy. Neurology 1987, 37:1525-1527.
29. Okazaki M., Adachi N., Ito M., Watanabe M., Watanabe Y., Kato M., Onuma T. One-year seizure prognosis in epilepsy patients treated with antidepressants. Epilepsy Behav. 2011, 22:331-335.
30. Oliver A.P., Luchins D.J., Wyatt R.J. Neuroleptic-induced seizures. An in vitro technique for assessing relative risk. Arch. Gen. Psychiatry 1982, 39:206-209.
31. Onuma T. Therapeutic approach to epileptic patients with psychiatric symptoms. Jpn. J. Psychiatry Treat. 1987, 2:553-560. ([in Japanese]).
32. Pauig P.M., Deluca M.A., Osterheld R.G. Thioridazine hydrochloride in the treatment of behavior disorders in epileptics. Am. J. Psychiatry 1961, 117:832-833.
33. Remick R.A., Fine S.H. Antipsychotic drugs and seizures. J. Clin. Psychiatry 1979, 40:78-80.
34. Toru M. Kou-Seishin-Yaku manual. Psychotropic Drug Manual 2001, Igaku Shoin, Tokyo, ([in Japanese]). 2nd ed.
35. Trimble M.R., Mula M. Psychopharmacology of patients with behavior disorders and epilepsy. Epilepsy. A Comprehensive Textbook 2008, 2215-2224. Lippincott Wiliams & Wilkins, Philadelphia. 2nd ed. J. Engel, T.A. Pedley (Eds.).
36. Woolley J., Smith S. Lowered seizure threshold on olanzapine. Br. J. Psychiatry 2001, 178:85-86.
37. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines 1992, World Health Organization, WHO, Geneva.